股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Home Control International Limited (於開曼群島註冊成立的有限公司) 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01747 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.01 USD | | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.01 USD ...

本公司董事（「董 事」）會（「董事會」）建議對本公司的現有組織章程細則（「細 則」） 作出建議修訂（「建議修訂」），以（其 中 包 括）： 因 此，董 事 會 建 議 採 納 新 的 本 公 司 組 織 章 程 細 則（載 有 建 議 修 訂）（「新細則」）以 取 代 或 摒 除 細 則。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 HOME CONTROL INTERNATIONAL LIMITED （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1747） 有關採納新組織章程細則的建議 本公告由Home Control International Limited（「本公司」）根據香港聯合交易所有限公 司證券上市規則（「上市規則」）第13.51(1)條 刊 發。 承董事會命 Home Control International Limited 行政總裁兼執行董 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | Home Control International Limited | | 股份代號 | 01747 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二五年十二月三十一日止年度之末期股息 | | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.0066 USD | | 股東批准日期 | 2026年6月12日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | ...

Financial Performance - The reported net profit for the year ending December 31, 2025, is $7,104,000, compared to $2,508,000 for the previous year, representing a significant increase of 184%[2] - Adjusted net profit (non-IFRS measure) for the same period is $9,498,000, up from $7,547,000, reflecting a growth of 25.8%[2] - Total revenue for the year is $109,399,000, an increase from $107,452,000, indicating a growth of 1.8%[3] - Gross profit for the year is $32,635,000, compared to $30,851,000 in the previous year, marking an increase of 5.8%[3] - The company reported a pre-tax profit of $8,502,000, up from $4,214,000, which is an increase of 101.4%[3] - Basic earnings per share for the year is $1.39, compared to $0.49 in the previous year, reflecting a growth of 184%[3] - The company’s total comprehensive income for the year is $7,304,000, compared to $2,362,000 in the previous year, representing an increase of 208%[3] - The company reported a profit attributable to owners of $7,104,000 for 2025, a significant increase from $2,508,000 in 2024, representing a growth of 184.5%[31] - The basic earnings per share for 2025 is $13.93, compared to $4.94 in 2024, reflecting a significant increase of 182.4%[31] Revenue and Regional Performance - North America revenue is projected to decrease from $42,515 thousand in 2024 to $26,425 thousand in 2025, a decline of approximately 37.8%[13] - Europe revenue is expected to increase from $43,317 thousand in 2024 to $50,385 thousand in 2025, a growth of about 16.5%[13] - Asia revenue is forecasted to rise significantly from $13,986 thousand in 2024 to $26,805 thousand in 2025, an increase of approximately 91.5%[13] - Revenue breakdown by region for 2025: North America at $26,425 (24.2%), Europe at $50,385 (46.1%), Asia at $26,805 (24.5%), and Latin America at $5,784 (5.3%)[54] - Customer contract revenue totals $109,399 thousand in 2025, up from $107,452 thousand in 2024, reflecting a growth of about 1.8%[17] Expenses and Cost Management - The company incurred restructuring and redundancy costs of $386,000 in 2025, down from $1,102,000 in 2024, showing a reduction of 65%[2] - Legal expenses amounted to $2,008,000 in 2025, compared to $708,000 in 2024, indicating an increase of 183%[2] - The cost of goods sold for components increased from $63,708 thousand in 2024 to $66,561 thousand in 2025, representing a rise of approximately 4.4%[25] - Research and development expenses decreased from $5,688 thousand in 2024 to $4,215 thousand in 2025, a reduction of about 26.0%[25] - Selling and distribution expenses rose from approximately $7.3 million in 2024 to about $7.8 million in 2025, mainly due to increased employee benefits and professional fees[59] - Administrative expenses were approximately $12 million for both years ending December 31, 2025, and 2024[60] Assets and Liabilities - Total assets increased to $78,409,000 in 2025 from $68,491,000 in 2024, representing a growth of approximately 14.1%[4] - Current liabilities decreased to $32,941,000 in 2025 from $42,808,000 in 2024, a reduction of about 23.2%[4] - Non-current liabilities rose to $602,000 in 2025 from $510,000 in 2024, an increase of approximately 18.0%[5] - Total equity increased significantly to $44,866,000 in 2025 from $25,173,000 in 2024, reflecting an increase of about 78.5%[5] - Cash and cash equivalents amounted to $19,443,000 in 2025, up from $12,000,000 in 2024, indicating a growth of approximately 62.0%[4] - Trade receivables slightly increased to $23,764,000 in 2025 from $23,575,000 in 2024, a marginal rise of about 0.8%[4] - The company reported a net asset value of $34,524,000 in 2025, compared to $14,327,000 in 2024, marking an increase of approximately 141.5%[4] Taxation - The total income tax expense for 2025 is $1,398,000, a decrease of 18.0% from $1,706,000 in 2024[7] - The effective tax rate for 2025 is 16.4%, a decrease from 40.5% in 2024, reflecting improved tax efficiency[7] - The company’s federal tax rate remains stable at 21% for 2025, consistent with 2024[27] Corporate Governance and Management - The company is committed to establishing good corporate governance practices to enhance transparency and accountability to shareholders[100] - The board is actively seeking a suitable candidate to fill the vacancy of the non-executive director position following the resignation of Alain Perrot[101] - The company will continue to review and improve its corporate governance practices to ensure effective leadership and enhance shareholder returns[102] - All directors have confirmed compliance with the standard code of conduct regarding securities trading as of December 31, 2025[103] - The company established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[104] Strategic Initiatives and Future Plans - The company plans to allocate around 70% of the net proceeds from a recent share placement to the development of AIoT technology and personal healthcare management products[47] - The company has established a wholly-owned subsidiary, Orbiva Limited, to further expand its healthcare business[46] - The company aims to enhance operational efficiency and profitability through strategic adjustments and by expanding its product lines with higher profit margins[48] - The company is focusing on cost management, expanding its sales team, and investing in R&D to diversify its business, particularly in home healthcare[51] - The company plans to develop AIoT technology and products, with a budget allocation of HKD 15.95 million (USD 2.05 million) for the first milestone, expected to be utilized by March 2026[92] Shareholder Information - The proposed final dividend for the fiscal year ending December 31, 2025, is $0.66 per share, totaling $3,552,000, pending approval at the upcoming annual general meeting[40] - A final dividend of USD 0.66 per share (approximately HKD 5.19 per share) has been proposed for the year ending December 31, 2025, compared to USD 0.25 per share (approximately HKD 1.93 per share) for the previous year[98] Market and Economic Conditions - The company has not utilized funds originally allocated for R&D and development of OTT products due to the unstable economic environment caused by COVID-19[88] - The company anticipates that the utilization of IPO proceeds will further improve its overall business performance[90] - The group continues to monitor foreign exchange risks and will take prudent measures to minimize currency exchange risks[83] - The group anticipates continued fluctuations in the exchange rates of the Singapore dollar, Chinese yuan, and US dollar[83]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 HOME CONTROL INTERNATIONAL LIMITED （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1747） 董事會會議日期 香 港，二 零 二 六 年 三 月 十 六 日 於 本 公 告 日 期，董 事 會 由 執 行 董 事 蕭 國 雄 先 生 及 楊 豪 放 先 生；非 執 行 董 事 馬 鷹 女 士；及 獨 立 非 執 行 董 事 葉 敏 先 生、陳 一 中 先 生 及Bernard Eng Chuan LIM先生組 成。 Home Control International Limited（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈， 本公司將於二零二六年三月二十六日（星 期 四）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考慮及通過本公司及其附屬公司截至二零二 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Home Control International Limited (於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01747 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.01 USD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.01 USD ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 HOME CONTROL INTERNATIONAL LIMITED （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1747） 截至二零二五年十二月三十一日止年度的 正面盈利預告 本公告乃由Home Control International Limited（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香 港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定 義 見 上 市 規 則）而 作 出。 本公司董事（「董 事」）會（「董事會」）謹此知會本公司股東（「股 東」）及 潛 在 投 資 者， 根據對本集團截至二零二五年十二月三十一日止年度（「年 內」）的未經審核綜 合 管 理 賬 目 的 初 步 評 估 及 董 事 會 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Home Control International Limited (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01747 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.01 USD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.01 USD ...

Group 1 - The company HOME CONTROL (01747) has signed a memorandum of understanding with Nanyang Technological University (NTU) to explore collaboration on AIoT-enabled healthcare solutions [1] - The collaboration may involve the initial planning and establishment of a personal healthcare AIoT platform, security for health management ecosystems, and the licensing and transfer of related intellectual property [1] - Any specific cooperation arrangements will be formalized through further negotiations and will require internal approvals from both parties before signing formal agreements [1] Group 2 - Orbiva Limited, a wholly-owned subsidiary of the company, has entered into an intellectual property licensing agreement with NTUitive Pte Ltd, a subsidiary of NTU [2] - The agreement allows Orbiva to use specific inventions and proprietary materials related to AI-assisted reliable home care intelligent agent systems, and to develop related systems, platforms, solutions, and services in the healthcare, IoT, and AIoT fields [2] - The memorandum of understanding aims to leverage the strengths, resources, and expertise of both the company and NTU for broader strategic cooperation, including the joint development of secure healthcare AIoT platforms and the creation of new business opportunities [2]

Group 1 - The company HOME CONTROL (01747) has signed a memorandum of understanding with Nanyang Technological University (NTU) to explore collaboration on AIoT-enabled healthcare solutions [1] - The collaboration may involve the initial planning and establishment of a personal healthcare AIoT platform, security of health management ecosystems, and the licensing and transfer of related intellectual property [1] - Any specific cooperation arrangements will be formalized through further negotiations and will require internal approvals before signing formal agreements [1] Group 2 - Orbiva Limited, a wholly-owned subsidiary of the company, has entered into an intellectual property licensing agreement with NTUitive Pte Ltd, a subsidiary of NTU [2] - The agreement allows Orbiva to use specific inventions and proprietary materials related to AI-assisted reliable home care intelligent agent systems for development in healthcare, IoT, and AIoT fields [2] - The memorandum aims to leverage the strengths, resources, and expertise of both the company and NTU for broader strategic cooperation, including the joint development of secure healthcare AIoT platforms [2]